Eben Tessari Kiniksa Pharmaceuticals, Ltd. (KNSA) insider trading activity

Eben Tessari is CHIEF OPERATING OFFICER of Kiniksa Pharmaceuticals, Ltd.. Currently has a direct ownership of 16,666 shares of KNSA, which is worth approximately $671,973. The most recent transaction as insider was on Sep 01, 2023, when has been sold 801 shares (Class A Common Share) at a price of $17.76 per share, resulting in proceeds of $14,225. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 16.7K

51.77% 3M change

82.64% 12M change

Total Value Held $671,973

Eben Tessari Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 01 2023	SELL Payment of exercise price or tax liability	$14,225 $17.76 p/Share	801 Reduced 0.65%	121,993 Class A Common Share
Sep 01 2023	BUY Exercise of conversion of derivative security	-	2,727 Added 2.17%	122,794 Class A Common Share
Apr 10 2023	SELL Payment of exercise price or tax liability	$8,578 $10.71 p/Share	801 Reduced 0.66%	120,067 Class A Common Share
Apr 10 2023	BUY Exercise of conversion of derivative security	-	2,727 Added 2.21%	120,868 Class A Common Share
Mar 20 2023	SELL Payment of exercise price or tax liability	$9,741 $11.12 p/Share	876 Reduced 0.74%	118,141 Class A Common Share
Mar 20 2023	BUY Exercise of conversion of derivative security	-	2,982 Added 2.44%	119,017 Class A Common Share
Mar 16 2023	SELL Payment of exercise price or tax liability	$6,612 $11.46 p/Share	577 Reduced 0.49%	116,035 Class A Common Share

Mar 16 2023	BUY Exercise of conversion of derivative security	-	1,964 Added 1.66%	116,612 Class A Common Share
Sep 02 2022	SELL Payment of exercise price or tax liability	$6,601 $11.44 p/Share	577 Reduced 0.5%	114,648 Class A Common Share
Sep 02 2022	BUY Exercise of conversion of derivative security	-	1,964 Added 1.68%	115,225 Class A Common Share
Jul 15 2022	BUY Grant, award, or other acquisition	$10,019 $9.56 p/Share	1,048 Added 0.92%	113,261 Class A Common Share
Mar 21 2022	SELL Payment of exercise price or tax liability	$16,042 $10.98 p/Share	1,461 Reduced 1.29%	112,213 Class A Common Share
Mar 21 2022	BUY Exercise of conversion of derivative security	-	4,611 Added 3.9%	113,674 Class A Common Share
Mar 16 2022	SELL Payment of exercise price or tax liability	$6,899 $10.13 p/Share	681 Reduced 0.62%	109,063 Class A Common Share
Mar 16 2022	BUY Exercise of conversion of derivative security	-	1,964 Added 1.76%	109,744 Class A Common Share
Jan 15 2022	BUY Grant, award, or other acquisition	$9,341 $9.63 p/Share	970 Added 0.89%	107,780 Class A Common Share
Jul 15 2021	BUY Grant, award, or other acquisition	$9,973 $11.49 p/Share	868 Added 0.81%	106,810 Class A Common Share

Eben Tessari

CHIEF OPERATING OFFICER

Hamilton, D0

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNSA shares.

Notify only if

Value

Insider Trading

Get notified when an Kiniksa Pharmaceuticals, Ltd. insider buys or sells KNSA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kiniksa Pharmaceuticals, Ltd.

Track Activities on KNSA

Account